EXAS

Analyst Note: EXAS (Exact Sciences Corporation)

Date: 2026-06-13 Current Price: $104.91

1. Structural Readiness

Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Pending confirmation of price action above the forming structure) Current Price: $104.91 Extension: — (No extension data available as the breakout has not fired) ATR Current: 0.3% (Sub-threshold volatility)

2. Thesis Layer

This is a TACTICAL, setup-led name. There is NO named secular thesis attached to this specific setup at this date. The conviction must be derived strictly from the quality of the structural setup and the underlying business fundamentals, rather than a macro or thematic tailwind. We are judging this name on its ability to execute its current operational plan and the structural integrity of its price action, without inventing a narrative that is not present in the evidence.

3. Business Overview

Company: Exact Sciences Corporation (EXAS) Industry: Healthcare / Diagnostics Business Model: Development and distribution of cancer screening and diagnostic tools.

Operational Context (as of 2026-06-13): Exact Sciences specializes in non-invasive and gene-expression based diagnostics. The company's portfolio is anchored by Cologuard, a stool-based DNA test for colorectal cancer (CRC) screening, and the Oncotype DX family of tests for breast, prostate, and colon cancers.

Key Performance Metrics & Guidance (Source: Earnings Transcript, 2025-11-04):

• Revenue Growth: Total revenue grew 20% year-over-year to $851 million in the third quarter, beating the midpoint of guidance by $43 million.
• Screening Segment: Screening revenue increased 22% year-over-year to $666 million, driven by an increase of 0.25 million people screened compared to the prior year.
• Guidance Revision: Management raised full-year revenue guidance to $3.22 billion – $3.235 billion (midpoint increase of $78 million).
• Profitability: Adjusted EBITDA guidance was raised to $470 million – $480 million, representing 14.7% adjusted EBITDA margins.
• Provider Adoption: Over 12,000 providers ordered Cologuard for the first time in Q3 (a 5-year high), and active ordering providers reached a record 200,000.
• Product Innovation: Cologuard Plus was highlighted for demonstrating 95% sensitivity and 94% specificity, leading to a 40% reduction in false positives compared to the original test.
• Market Opportunity: Management noted that approximately half of the U.S. population eligible for CRC screening is not up to date, with payers and health systems actively seeking solutions to close these gaps.

4. Archetype and Conviction

Archetype: Margin Inflector Fit Analysis: The company fits the Margin Inflector archetype. The evidence from the November 2025 earnings call demonstrates a clear trajectory of expanding margins (14.7% adjusted EBITDA) alongside top-line growth (20% YoY). The introduction of Cologuard Plus and the expansion of the provider base (200k active providers) suggest operational leverage is being realized.

Valuation & Financial Spine:

• Forward Consensus EPS: FY1: $0.18; FY2: $1.0925.
• Coverage: Financial spine coverage is "complete."

Conviction Stack:

• Thesis Strength: Low (Tactical/Setup-led only; no macro thesis).
• Evidence Quality: High. The earnings data is specific, quantitative, and shows a clear beat on both revenue and margins.
• Structural Quality: Moderate. The setup is "forming," meaning the structural integrity is present but the breakout catalyst has not yet occurred.
• Setup Readiness: Low. The sub-threshold ATR (0.3%) and lack of a defined breakout level indicate the market is currently in a low-volatility consolidation phase.
• Rerating Potential: Moderate. The margin expansion (14.7% EBITDA) provides a fundamental floor for valuation, but the stock requires a structural breakout to trigger a re-rating.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued provider adoption rates exceeding the 12,000 new providers per quarter seen in Q3 2025.
• Further margin expansion beyond the 14.7% guidance, validating the "Margin Inflector" thesis.

What Would Invalidate the Case:

• A failure to meet the raised full-year revenue guidance of $3.22B–$3.235B.
• A significant drop in the number of active ordering providers.

Gaps in Evidence:

• Breakout Confirmation: There is no evidence of a breakout event having occurred as of 2026-06-13.
• Long-term Pipeline: While Cologuard Plus and Oncotype DX are detailed, specific data on the commercialization timeline or revenue contribution of "Cancerguard" (mentioned as launched) is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Raised full-year revenue guidance to $3.22B-$3.235B; 14.7% adjusted EBITDA margins; 200,000 active ordering providers (record high); Cologuard Plus showing 40% reduction in false positives. Key risks: Sub-threshold ATR (0.3%) indicates lack of momentum; setup is forming but not confirmed; no named secular thesis to provide tailwind; reliance on payer adoption for screening volume. Sizing hint: Position size should be conservative given the "forming" status and low volatility; wait for structural confirmation before adding. Expected path: Management expectations of margin expansion and provider growth should support the stock if the structural breakout occurs; the stock likely needs to consolidate further to build the necessary volatility for a breakout. Expected horizon: 3 to 6 months for the structural setup to resolve into a confirmed breakout or invalidation.